Peptide Therapeutics Market By Application (Metabolic, Oncology, Gastrointestinal, Neurological, Cardiovascular, Others), By Route of administration (Oral, Parenteral), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Peptide Therapeutics Market

A special class of pharmacological drugs known as therapeutic peptides is made up of a sequence of well-ordered amino acids and typically has a molecular weight of 500–5000 Da. Approved peptides drugs are indicated to treat a wide array of clinical indications, including diabetes, gastric & metabolic disorders, and hormonal disorders. 

Increase in elderly population and surge in cases of chronic diseases are the major drivers of this market. Peptide therapeutics are used for treating metabolic, oncology, gastrointestinal, neurological, cardiovascular and other diseases According to the Centre of Disease Control and Prevention one person dies every 34 seconds in the U.S. from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020—that’s 1 in every 5 deaths. Thus, the rise in the number of the cardiovascular disease cases around the globe along with rise in the number of the geriatric patients, leads to the growth of the market. 

Furthermore, innovations, development of advanced technologies, are the peptide therapeutics market trends adopted by the key players and increasing awareness for peptide therapeutics fuels the market growth. However, high cost associated with drug discovery and less bioavailability of peptides, is expected to hinder the market growth. Conversely increasing growth opportunity in emerging markets, rising health care expenditure is a great opportunity for key players to invest in the forecast period especially in the developing economies.

The peptide therapeutics market analysis is segmented by application, route of administration, distribution channel and region. By application, the market is segmented into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. The metabolic segment dominated the peptide therapeutics market share in 2021, accounting owing to high prevalence of metabolic disorders and growing geriatric population susceptible to metabolic disorder. The oncology segment is expected to witness highest CAGR during the forecast period, owing to rise in cases of cancer globally and the presence of a strong product pipeline. 

Depending on route of administration, the market is divided into oral and parenteral. The parenteral segment dominated the peptide therapeutics market size in 2021, owing to high rate of acceptance, quick drug delivery, and simple application.  The oral segment is expected to witness highest CAGR during the peptide therapeutics market forecast period owing to compliance with oral route and acceptance by patients.

Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the peptide therapeutics market size in 2021, with owing to all primarily responsible for monitoring the availability of all medications used in hospitals. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to maintenance of treatment for long time and easy availability of drugs.

North America accounted for a majority of the global peptide therapeutics market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in peptide therapeutics development techniques, rise in cardiovascular diseases, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in geriatric population, development of healthcare infrastructure and increase in investments projects in the region.

Key findings of the study

•    By application, the metabolic segment was the highest contributor to the peptide therapeutics industry in 2021.

•    By route of administration, the parenteral segment was the highest contributor to the peptide therapeutics industry in 2021.

•    Depending on distribution channel, the hospital pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.

•    Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global peptide therapeutics market was valued at $33,257.72 million in 2021, and is estimated to reach $64,336.12 million by 2031, growing at a CAGR of 6.8% from 2022 to 2031. A peptide is a small, chemically bound chain of amino acids, usually between two and fifty amino acids (called peptide bonds). Peptides are smaller than proteins, consisting of about 2 to 50 amino acids. Peptides employed in the therapy of diseases are known as peptide therapies. Peptide treatments replicate such roles that naturally occurring peptides can perform as hormones, growth factors, ion channel ligands, and anti-effectiveness. Given that peptides can be metabolized by the body, peptide therapeutics are thought to be generally safe and well-tolerated.The major factors that drive the growth of the peptide therapeutics market are rise in incidence of chronic diseases such as diabetes, cancer, significant development of peptide therapeutics and growth in R & D for peptide therapeutics, are the factors attributed to the growth of the peptide therapeutics market. In addition, surge in the R & D by the key players is a key trend of the market, which is expected to fuel the growth in the forecast period.

Rise in prevalence of the chronic diseases drives peptide therapeutics market. For an instance, according to the NCBI, National Center for Biotechnology Information, gastrointestinal diseases affect an estimated 60 to 70 million people annually in America and having colorectal cancer as the 2nd leading cancer diagnosed among American men and women. Thus, globally, there has been an increase in prevalence of chronic diseases. which further highlights the need for the peptide therapeutics causing the market growth.

However, poor bioavailability of peptides and high cost associated with drug development are expected to hinder the growth of the market. Conversely, growth opportunities in emerging market to suffice the consumer demands is expected to provide a great opportunity for the investors to invest in the market.

The global peptide therapeutics market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is categorized into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. By route of administration, it is divided into oral and parenteral. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Hospital pharmacies segment is further bifurcated as private and public. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc, Amgen Inc., Bausch Health Companies Inc, Eli Lilly and company, Ever Neuro Pharma GmbH, GalaxoSmithKline plc, Novo Nordisk, Pfizer Inc, Sanofi-GSK and Takeda Pharmaceutical Company Limited.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peptide therapeutics market analysis from 2021 to 2031 to identify the prevailing peptide therapeutics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the peptide therapeutics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global peptide therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Abbvie ( Allergan

Scope of Peptide Therapeutics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

3.7.Patent Landscape

4.1 Overview

4.1.1 Market size and forecast

4.2 Metabolic

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Oncology

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Gastrointestinal

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Neurological

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

4.6 Cardiovascular

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market analysis by country

4.7 Others

4.7.1 Key market trends, growth factors and opportunities

4.7.2 Market size and forecast, by region

4.7.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Oral

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Parenteral

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Hospital pharmacies Peptide Therapeutics Market by Hospital type

6.2.4.1 Private Market size and forecast, by region

6.2.4.2 Public Market size and forecast, by region

6.3 Drug store and retail pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Online pharmacies

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Application

7.2.3 North America Market size and forecast, by Route of administration

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.4.1 North America Hospital pharmacies Peptide Therapeutics Market by Hospital type

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Application

7.2.5.1.2 Market size and forecast, by Route of administration

7.2.5.1.3 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Application

7.2.5.2.2 Market size and forecast, by Route of administration

7.2.5.2.3 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Application

7.2.5.3.2 Market size and forecast, by Route of administration

7.2.5.3.3 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Application

7.3.3 Europe Market size and forecast, by Route of administration

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.4.1 Europe Hospital pharmacies Peptide Therapeutics Market by Hospital type

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Application

7.3.5.1.2 Market size and forecast, by Route of administration

7.3.5.1.3 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Application

7.3.5.2.2 Market size and forecast, by Route of administration

7.3.5.2.3 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Application

7.3.5.3.2 Market size and forecast, by Route of administration

7.3.5.3.3 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Application

7.3.5.4.2 Market size and forecast, by Route of administration

7.3.5.4.3 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Application

7.3.5.5.2 Market size and forecast, by Route of administration

7.3.5.5.3 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Application

7.3.5.6.2 Market size and forecast, by Route of administration

7.3.5.6.3 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Application

7.4.3 Asia-Pacific Market size and forecast, by Route of administration

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.4.1 Asia-Pacific Hospital pharmacies Peptide Therapeutics Market by Hospital type

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Application

7.4.5.1.2 Market size and forecast, by Route of administration

7.4.5.1.3 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Application

7.4.5.2.2 Market size and forecast, by Route of administration

7.4.5.2.3 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by Application

7.4.5.3.2 Market size and forecast, by Route of administration

7.4.5.3.3 Market size and forecast, by Distribution Channel

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by Application

7.4.5.4.2 Market size and forecast, by Route of administration

7.4.5.4.3 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Application

7.4.5.5.2 Market size and forecast, by Route of administration

7.4.5.5.3 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Application

7.4.5.6.2 Market size and forecast, by Route of administration

7.4.5.6.3 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Application

7.5.3 LAMEA Market size and forecast, by Route of administration

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.4.1 LAMEA Hospital pharmacies Peptide Therapeutics Market by Hospital type

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Application

7.5.5.1.2 Market size and forecast, by Route of administration

7.5.5.1.3 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Application

7.5.5.2.2 Market size and forecast, by Route of administration

7.5.5.2.3 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Application

7.5.5.3.2 Market size and forecast, by Route of administration

7.5.5.3.3 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Application

7.5.5.4.2 Market size and forecast, by Route of administration

7.5.5.4.3 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Eli Lilly and Company

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Amgen Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Pfizer Inc.

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Takeda Pharmaceutical Company Limited

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Novo Nordisk A/S

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Sanofi SA

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Ever Neuro Pharma GmbH

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Baush Health

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 GlaxoSmithKline plc

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Abbvie ( Allergan)

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 2. PEPTIDE THERAPEUTICS MARKET, FOR METABOLIC, BY REGION, 2021-2031 ($MILLION)

TABLE 3. PEPTIDE THERAPEUTICS MARKET FOR METABOLIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. PEPTIDE THERAPEUTICS MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)

TABLE 5. PEPTIDE THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. PEPTIDE THERAPEUTICS MARKET, FOR GASTROINTESTINAL, BY REGION, 2021-2031 ($MILLION)

TABLE 7. PEPTIDE THERAPEUTICS MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. PEPTIDE THERAPEUTICS MARKET, FOR NEUROLOGICAL, BY REGION, 2021-2031 ($MILLION)

TABLE 9. PEPTIDE THERAPEUTICS MARKET FOR NEUROLOGICAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. PEPTIDE THERAPEUTICS MARKET, FOR CARDIOVASCULAR, BY REGION, 2021-2031 ($MILLION)

TABLE 11. PEPTIDE THERAPEUTICS MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 12. PEPTIDE THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. PEPTIDE THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 15. PEPTIDE THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)

TABLE 16. PEPTIDE THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. PEPTIDE THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)

TABLE 18. PEPTIDE THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 20. PEPTIDE THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 21. PEPTIDE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 22. GLOBAL HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)

TABLE 23. PEPTIDE THERAPEUTICS MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)

TABLE 24. PEPTIDE THERAPEUTICS MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)

TABLE 25. PEPTIDE THERAPEUTICS MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 26. PEPTIDE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 27. PEPTIDE THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 28. PEPTIDE THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 29. PEPTIDE THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 30. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 31. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 32. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)

TABLE 34. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 35. U.S. PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 36. U.S. PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 37. U.S. PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 38. CANADA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 39. CANADA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 40. CANADA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 41. MEXICO PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 42. MEXICO PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 43. MEXICO PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 44. EUROPE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 45. EUROPE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 46. EUROPE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 47. EUROPE HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)

TABLE 48. EUROPE PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 49. GERMANY PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 50. GERMANY PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 51. GERMANY PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 52. FRANCE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 53. FRANCE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 54. FRANCE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 55. UK PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 56. UK PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 57. UK PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 58. ITALY PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 59. ITALY PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 60. ITALY PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 61. SPAIN PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 62. SPAIN PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 63. SPAIN PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 64. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 65. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 66. REST OF EUROPE PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 69. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)

TABLE 71. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 72. JAPAN PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 73. JAPAN PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 74. JAPAN PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 75. CHINA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 76. CHINA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 77. CHINA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 78. INDIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 79. INDIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 80. INDIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 81. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 82. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 83. AUSTRALIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 84. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 85. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 86. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 87. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 88. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 89. REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 90. LAMEA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 91. LAMEA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 92. LAMEA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 93. LAMEA HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET, BY HOSPITAL TYPE, 2021-2031 ($MILLION)

TABLE 94. LAMEA PEPTIDE THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 98. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 99. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 100. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 101. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 102. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 103. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 104. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 105. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 106. REST OF LAMEA PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 107.ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 108.ELI LILLY AND COMPANY: OPERATING SEGMENTS

TABLE 109.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 110.ELI LILLY AND COMPANY: NET SALES,

TABLE 111.ELI LILLY AND COMPANY: KEY STRATERGIES

TABLE 112.AMGEN INC.: COMPANY SNAPSHOT

TABLE 113.AMGEN INC.: OPERATING SEGMENTS

TABLE 114.AMGEN INC.: PRODUCT PORTFOLIO

TABLE 115.AMGEN INC.: NET SALES,

TABLE 116.AMGEN INC.: KEY STRATERGIES

TABLE 117.PFIZER INC.: COMPANY SNAPSHOT

TABLE 118.PFIZER INC.: OPERATING SEGMENTS

TABLE 119.PFIZER INC.: PRODUCT PORTFOLIO

TABLE 120.PFIZER INC.: NET SALES,

TABLE 121.PFIZER INC.: KEY STRATERGIES

TABLE 122.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 123.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS

TABLE 124.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 125.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,

TABLE 126.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

TABLE 127.NOVO NORDISK A/S: COMPANY SNAPSHOT

TABLE 128.NOVO NORDISK A/S: OPERATING SEGMENTS

TABLE 129.NOVO NORDISK A/S: PRODUCT PORTFOLIO

TABLE 130.NOVO NORDISK A/S: NET SALES,

TABLE 131.NOVO NORDISK A/S: KEY STRATERGIES

TABLE 132.SANOFI SA: COMPANY SNAPSHOT

TABLE 133.SANOFI SA: OPERATING SEGMENTS

TABLE 134.SANOFI SA: PRODUCT PORTFOLIO

TABLE 135.SANOFI SA: NET SALES,

TABLE 136.SANOFI SA: KEY STRATERGIES

TABLE 137.EVER NEURO PHARMA GMBH: COMPANY SNAPSHOT

TABLE 138.EVER NEURO PHARMA GMBH: OPERATING SEGMENTS

TABLE 139.EVER NEURO PHARMA GMBH: PRODUCT PORTFOLIO

TABLE 140.EVER NEURO PHARMA GMBH: NET SALES,

TABLE 141.EVER NEURO PHARMA GMBH: KEY STRATERGIES

TABLE 142.BAUSH HEALTH: COMPANY SNAPSHOT

TABLE 143.BAUSH HEALTH: OPERATING SEGMENTS

TABLE 144.BAUSH HEALTH: PRODUCT PORTFOLIO

TABLE 145.BAUSH HEALTH: NET SALES,

TABLE 146.BAUSH HEALTH: KEY STRATERGIES

TABLE 147.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 148.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 149.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 150.GLAXOSMITHKLINE PLC: NET SALES,

TABLE 151.GLAXOSMITHKLINE PLC: KEY STRATERGIES

TABLE 152.ABBVIE ( ALLERGAN): COMPANY SNAPSHOT

TABLE 153.ABBVIE ( ALLERGAN): OPERATING SEGMENTS

TABLE 154.ABBVIE ( ALLERGAN): PRODUCT PORTFOLIO

TABLE 155.ABBVIE ( ALLERGAN): NET SALES,

TABLE 156.ABBVIE ( ALLERGAN): KEY STRATERGIES LIST OF FIGURES

FIGURE 1.PEPTIDE THERAPEUTICS MARKET SEGMENTATION

FIGURE 2.PEPTIDE THERAPEUTICS MARKET,2021-2031

FIGURE 3.PEPTIDE THERAPEUTICS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.PEPTIDE THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.PATENT ANALYSIS BY COMPANY

FIGURE 13.PATENT ANALYSIS BY COUNTRY

FIGURE 14.PEPTIDE THERAPEUTICS MARKET,BY APPLICATION,2021(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF METABOLIC PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NEUROLOGICAL PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 21.PEPTIDE THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ORAL PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF PARENTERAL PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 24.PEPTIDE THERAPEUTICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES PEPTIDE THERAPEUTICS MARKET,2021-2031(%)

FIGURE 28.PEPTIDE THERAPEUTICS MARKET BY REGION,2021

FIGURE 29.U.S. PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 30.CANADA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 31.MEXICO PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 32.GERMANY PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 33.FRANCE PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 34.UK PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 35.ITALY PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 36.SPAIN PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 37.REST OF EUROPE PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 38.JAPAN PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 39.CHINA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 40.INDIA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 41.AUSTRALIA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 42.SOUTH KOREA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 43.REST OF ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 44.BRAZIL PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 45.SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 46.SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 47.REST OF LAMEA PEPTIDE THERAPEUTICS MARKET,2021-2031($MILLION)

FIGURE 48. TOP WINNING STRATEGIES, BY YEAR

FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 52.COMPETITIVE DASHBOARD

FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 54.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)

FIGURE 55.AMGEN INC..: NET SALES ,($MILLION)

FIGURE 56.PFIZER INC..: NET SALES ,($MILLION)

FIGURE 57.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)

FIGURE 58.NOVO NORDISK A/S.: NET SALES ,($MILLION)

FIGURE 59.SANOFI SA.: NET SALES ,($MILLION)

FIGURE 60.EVER NEURO PHARMA GMBH.: NET SALES ,($MILLION)

FIGURE 61.BAUSH HEALTH.: NET SALES ,($MILLION)

FIGURE 62.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)

FIGURE 63.ABBVIE ( ALLERGAN).: NET SALES ,($MILLION